Anglikang Adenosylcobalamin Capsules Obtain Drug Registration Certificate
March 6, 2026
Source: drugdu
31
March 4th - AnglikangThe company announced that it recently obtained adenosine cobalt from the National Medical Products Administration.The company has obtained the Drug Registration Certificate for Amino Capsules. This drug is indicated for the adjunctive treatment of megaloblastic anemia, nutritional anemia, anemia of pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, nerve palsy, as well as nutritional disorders and radiation- and drug-induced leukopenia. The company received the notification of acceptance for its marketing authorization application in June 2024 and recently received approval from the National Medical Products Administration.
The announcement indicates that, according to relevant national policies, obtaining the Drug Registration Certificate is considered equivalent to passing the consistency evaluation. This drug registration certificate will further enrich the company's product pipeline; however, drug sales are easily affected by factors such as national policies and changes in the market environment, and there is considerable uncertainty regarding specific sales performance.
https://finance.eastmoney.com/a/202603053663192752.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Two Minoxidil Topical Solution Applications from its Subsidiary Approved March 6, 2026
- Zhejiang Medicine’s ARX305 Initiates Phase II Clinical Trial March 6, 2026
- Indacaterol Mometasone Inhalation Powder Clinical Trial Approved for Asthma Treatment March 6, 2026
- Harsco Pharmaceutical’s innovative drug HSK50042 tablets receive clinical approval for a new indication March 6, 2026
- Clinical trial application for HLX97 approved by the National Medical Products Administration March 6, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
